Clinical Trials Logo
  1. Home
  2. Heartburn
  3. NCT00382577
  4. Details
NCT00382577 Clinical Trial

Efficacy and Safety of Itopride vs Placebo in Heartburn

Heartburn Clinical Trial

Official title:
A Randomized, Double-blind, Two Period, Crossover Study to Evaluate the Effects of a Single Dose of Itopride 200 mg on Esophageal and Gastric pH and Reflux in Patients With Heartburn

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00382577
Other study ID # ITOLES06-01
Secondary ID
Status Completed
Phase Phase 3
First received September 27, 2006
Last updated February 7, 2017
Start date October 2006
Est. completion date December 2006

Study information
Verified date February 2017
Source Forest Laboratories
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of itopride in patients with heartburn.

Recruitment information / eligibility
Status Completed
Enrollment 48
Est. completion date December 2006
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Otherwise healthy males and females aged 18-70, with at least 3 episodes of heartburn or acid regurgitation per week.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Itopride

• Placebo

Locations
Country Name City State
United States The Oklahoma Foundation for Digestive Research Oklahoma City Oklahoma

Sponsors (1)
Lead Sponsor Collaborator
Forest Laboratories

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary 24-hour pH Monitoring after 5 days of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT06094062 - Smartphone App-assisted PPI N/A
Completed NCT00481949 - Assessment of Gastro-esophageal Reflux Using Endo-Flip vs Bravo N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Recruiting NCT01696734 - Domperidone in Treating Patients With Gastrointestinal Disorders Phase 3
Recruiting NCT02105090 - Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy Phase 4
Completed NCT01338077 - Efficacy and Safety of Sodium Alginate Oral Suspension to Treat Non-erosive Gastro-esophageal Reflux Disease Phase 3
Completed NCT01005251 - Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI Phase 2
Terminated NCT00536328 - What is the Predictive Value of the Reflux Impact Scale N/A
Completed NCT00236184 - E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers Phase 3
Completed NCT00236197 - E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers Phase 3
Completed NCT00236392 - A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD) Phase 3
Completed NCT04153552 - Upset Stomach Relief for Mild and Moderate Indigestion and Heartburn N/A
Recruiting NCT06075082 - The Effect of the LEFT Smartwatch App as Sleep Positional Therapy for Nocturnal Gastroesophageal Reflux Symptoms. N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Recruiting NCT02277886 - Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Phase 4
Completed NCT01249651 - To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Phase 4
Completed NCT00588939 - Confocal Laser Microscopy in Non Erosive Reflux Disease N/A
Completed NCT00206024 - Acid-Associated Heartburn Symptoms and Dose of Esomeprazole Phase 4
Recruiting NCT05976165 - A Study of Breath Testing for Small Intestinal Bacterial Overgrowth N/A
Not yet recruiting NCT06098742 - Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers N/A